J&J is forced to sus­pend re­cruit­ment in PhI di­a­betes study, rais­ing ques­tions about an­oth­er Han­mi drug

J&J has run in­to a prob­lem with a Phase I di­a­betes drug — JNJ-64565111 — in-li­censed from South Ko­rea’s Han­mi. The in­ves­ti­ga­tors on the study re­port­ed on clin­i­cal­tri­als.gov that the tri­al has sus­pend­ed pa­tient re­cruit­ment, and a spokesper­son for J&J tells me that the de­lay was due to “a man­u­fac­tur­ing-re­lat­ed de­lay.”

“Our part­ner­ship with Han­mi re­mains strong re­gard­ing this drug can­di­date and we look for­ward to restart­ing the study,” she added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER